Zeybek, B., Manzano, A., Bianchi, A., Bonazzoli, E., Bellone, S., Buza, N., . . . Santin, A. (2020). Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Sci Rep.
Stile di citazione ChicagoZeybek, Burak, et al. "Cervical Carcinomas That Overexpress Human Trophoblast Cell-surface Marker (Trop-2) Are Highly Sensitive to the Antibody-drug Conjugate Sacituzumab Govitecan." Sci Rep 2020.
Citazione MLAZeybek, Burak, et al. "Cervical Carcinomas That Overexpress Human Trophoblast Cell-surface Marker (Trop-2) Are Highly Sensitive to the Antibody-drug Conjugate Sacituzumab Govitecan." Sci Rep 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.